DOCSLIB.ORG

APOTEX, INC. Preparation Questions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
APOTEX, INC. Preparation Questions APOTEX, INC. and compliance requirements. We value and respect our employees, our business partners, our Preparation questions: Based on your reading of the suppliers, our customers and the communities we materials, together with your understanding of serve while operating with accountability and strategies for generic drug manufacturers, what are integrity in everything we do. the key challenges that Apotex faces in its market Background segment? o Apotex Inc. is the largest Canadian-owned pharmaceutical company. From its 2 Contents employees, 5,000 square foot beginning, the A. Company overview (November 2012, updated company has grown to employ over 6,800 October 2013) people in research, development, B. Apotex generic drug approvals in the US, manufacturing and distribution facilities 2001-2012 world-wide. The Canadian operations of the C. Example of a successful introduction (Norvasc) Apotex Group of Companies with 5,800 D. Example of an unsuccessful introduction employees now occupy over 3.4 million (Plavix) square feet in Montreal, Richmond Hill, E. 2008-2012: GMP issues and subsequent Toronto, Etobicoke, Mississauga, Brantford, litigation Windsor, Winnipeg, London, Calgary and Vancouver. Apotex produces more than 300 generic pharmaceuticals in approximately A. COMPANY OVERVIEW 4,000 dosages and formats which, in Canada, are used to fill over 85 million prescriptions a Background year - the largest amount of any Headquarters: 150 Signet Dr., Toronto, ON pharmaceutical company in this country. M9L 1T9 o Today, Apotex is a necessary and trusted member of Canada’s healthcare community. Employees: 7,500 (2,500 outside Canada) The company’s pharmaceuticals can be found Estimated sales: Greater than $1 billion in virtually every pharmacy and healthcare (2012 sales in Canada: ~$1.25 billion) facility in Canada and are exported to over Founded: 1974 115 countries around the globe. Export markets represent an ever growing portion of Production & development the total sales. Apotex has also established a Global capacity: 30 billion dosages per year. presence through subsidiaries, joint ventures 300 medicines in 4,000 dosages and formats or licensing agreements in Australia, 88 million prescriptions per year Belgium, Czech Republic, Italy, Mexico, Exported to 115 countries. Netherlands, New Zealand, Poland, Turkey, 600 products under development and the UK, to name just a few. Healthcare Plans to spend $2 billion over the next 10 years professionals around the world rely on on R&D. Apotex for quality and value. [Note: CapitalIQ estimates that Apotex markets Key executives products through distributors in Argentina, Dr. Bernard (Barry) Charles Sherman - Aruba, Bahamas, Bahrain, Barbados, Founder Belarus, Bermuda, Botswana, the Cayman Mr. Jacob (Jack) M. Kay - President and Islands, China, Costa Rica, Curacao, the Chief Operating Officer Eastern Caribbean Islands, El Salvador, Guyana, Haiti, Hong Kong, Hungary, Information from Apotex Home Site (2012-2013) Indonesia, Iran, Jamaica, Kuwait, Lebanon, Libya, Malaysia, Moldova, Nigeria, Our Mission: Apotex is an independent, Nicaragua, Panama, the Philippines, Russia, dynamic, Canadian pharmaceutical company Saudi Arabia, Singapore, Taiwan, Thailand, committed to R&D, manufacturing and Trinidad and Tobago, Turkey, Ukraine, the distributing a broad range of high-quality, United Arab Emirates, the United Kingdom, affordable medicines to patients, healthcare Vietnam, Yemen, and Zimbabwe; with providers, payers and governments worldwide. facilities in Australia, Belgium, the Czech We will always meet global regulatory, quality Republic, Italy, Mexico, the Netherlands, 1 New Zealand, Poland, Turkey, and the skills and experience needed to succeed in United Kingdom.] areas of sales, marketing, product o Although the company’s own business is development, clinical development, developing and manufacturing generic regulatory and medical affairs. pharmaceuticals, the success of Apotex has o Apotex has strong relationships with enabled it to diversify into a number of other regulatory agencies enabling us to develop health-related areas. The Apotex successful registration strategies in all major Pharmaceutical Group of Companies also markets. researches, develops, manufactures and o The success of Apotex has been built not distributes fine chemicals, non-prescription only on developing a broad product portfolio and private label medicines, and disposable but also in launching the difficult to do plastics for medical use. generics — taking on challenges of developing difficult APIs and formulations, Research and Development products with difficult clinical and regulatory o Research at Apotex includes the development pathways, and patent challenges. Some of our of both generic and innovative successes have been achieved in pharmaceuticals. collaboration with third parties. New generic products have been a critical o o Apotex offers a cost effective alternative to component of Apotex's growth and have potential partners who are interested in resulted in the development of substantial registering and commercializing their generic expertise in formulation development, pharmaceuticals in Apotex target markets. synthetic and analytical chemistry. o Our interest in in-licensing varies depending o Research on new chemical entities is carried on territory. We welcome you to submit your out by ApoPharma Inc., a Subsidiary of opportunity for our consideration. Apotex, where our current focus is in the areas of hematology, neurodegenerative Recent activity: 2011-2012 diseases and psoriasis. Apotex's first o October 2012: Opens offices in Saudi Arabia innovative drug, Ferriprox™, is approved in o October 2012: Divest ten older products to over 50 countries for treating iron overload in AA Pharma [Note: AA Pharma is based in Thalassemia. More recently, extensive Vaughan, Ontario; Hoovers estimates the research has begun on developing permeant company has about ten employees and annual iron chelators for the treatment of several sales of $1 million; the company states that it neurodegenerative diseases where the impact focuses on “legacy pharmaceuticals”, with a of modifying intracellular iron metabolism is product line of over 50 drugs in 2012] being studied both in animals and humans. o April 2012: Launch of Apo-Rosuvastatin Our newest area of research, psoriasis, saw (Crestor statin; AstraZeneca) ApoPharma initiate clinical trials in 2008 to o December 2011: Federal Court of Canada evaluate the safety and efficacy of a novel ruled in favour of Apotex for generic Plavix dipeptide that has demonstrated a remarkable in Canada. Apotex challenged the Sanofi- safety profile in animal toxicity testing. aventis Plavix® patents for over 8 years; o R & D expenditures for Apotex in 2007 was annual Plavix market in Canada is about over $181 million, representing close to 18% $300 million. of sales, placing Apotex in the top 10 o November 2011: Launched generic research and development companies and in Esomeprazole version of AstraZeneca's the top two pharmaceutical companies in Nexium®, a gastric proton pump inhibitor Canada (PPI). Brand product market is about $300 million per year. Apotex now offer 4 out of 5 Business Development: Partnering major gastric PPI molecules - Omeprazole, o Opportunity: Apotex offers a cost effective Pantoprazole, Lansoprazole, & alternative to potential partners who are Esomeprazole. interested in registering and commercializing o October 2011: Successful patent challenge their generic pharmaceuticals in Apotex for generic Xalatan® (eye pressure drug; target markets. Pfizer), nearly three years prior to patent o Committed to advancing generics, Apotex expiry. has been in the business for over 36 years and during that time has developed a deep understanding of the global market and the 2 Information from Hoovers (2011-2012) Apotex's overall strategy of Apotex strives to be at the apex of the continually evaluating its portfolio and selling Canadian generics industry. The company is one those medications it thinks could be better of Canada's leading generic drug makers, marketed by another pharmaceutical company. producing more than 250 generic drugs AA Pharma will attempt to boost sales of the in thousands of dosages and formulations. Its acquired prescription medications. product line includes generic equivalents Making generic versions of other companies' of Merck's Claritin (allergy medication), Pfizer's products can be a risky business. For example, Norvasc (hypertension), and GlaxoSmithKline's Apotex came into the spotlight in 2006 when it antidepressant, Paxil. Apotex markets its drugs flooded the market with a generic version throughout Canada and the US, as well as in of Sanofi and Bristol-Myers Squibb's blood about 115 other countries in the Asia/Pacific thinner Plavix (one of the world's top-selling region, Africa, Europe, Latin America, and the drugs). The two companies sued and Apotex was Middle East. The company also has a ordered to stop distribution of its generic version manufacturing agreement with The Harvard of the drug about a month after sales began, but Drug Group. the bout of competition had already had a Apotex conducts most of its business in North significant negative impact on Plavix's America, but it is expanding its global sales sales. Litigation over the matter dragged on for network through partnerships and about four years before a judge in late acquisitions. It operates across a full range of 2010 ordered Apotex to pay Bristol-Myers
Load more

Recommended publications
  • Downloads but Many Other Countries — Such As the RCMP Said the Policy Revisions /JJ Release on April30.Pdf)
    CMAJ News For the record Published at www.cmaj.ca between Apr. The new warning letter regards in persistent or significant disability or 20 and May 18 breaches uncovered during a July– incapacity, be life-threatening or result August 2009 FDA inspection of an in death. Apotex receives second FDA Apotex facility located at 150 Signet The report indicates that there has Drive in Toronto, during which “sev- been a steady increase of adverse reac- warning eral violations that are identical” to tion reports since 2001, when roughly those found during the inspection of the 11 000 incidents were reported (www.hc he United States Food and Drug Etobicoke facility were discovered. -sc.gc.ca/dhp-mps/alt_formats/pdf/med Administration (FDA) has “These identical CGMP violations eff/bulletin/carn-bcei_v20n2-eng.pdf). T issued a second warning letter demonstrated a lack of adequate Roughly 70% (18 301) of 2009 inci- in a year to Toronto, Ontario-based process controls and raised serious dents involved pharamaceuticals, while generic drug manufacturer Apotex Inc. questions regarding your corporation’s 23% (5998) involved biotechnology for lapses in good manufacturing prac- quality and production systems,” the products. There were 833 adverse reac- tices. warning letter states. tion reports involving biologics, 516 The violations cause Apotex drug The violations included contamina- involving natural health products, 379 products to be considered “adulterated” tion of a diabetes drug with an “active involving radiopharmaceuticals and 34 within US regulations
    [Show full text]
  • MB-01 COVER.Indd
    SHANAH TOVAH uc,f, vcuy vbak INFLUENCERS Plus: Fiction by Ella Burakowski M THE CANADIAN JEWISH NEWS B2 [ RH 5776 ] SEPTEMBER 10, 2015 Supreme Court judge broke new ground A colourful life Employment, she coined the term and in the spotlight the concept of “employment equity,” as a strategy to remedy workplace dis- arbara Amiel has been called a lot of crimination faced by women, Aborigin- B things, but boring shouldn’t be one of al Peoples, people with disabilities and them. visible minorities. Known for her outspoken, politically That same year she was the first conservative column in Maclean’s maga- woman chair of the Ontario Labour Re- zine as much as for her marriage to for- lations Board and later became the first mer media baron Conrad Black, Amiel is Barbara Amiel Rosalie Silberman Abella woman in the British Commonwealth to a British Canadian journalist, writer and head a law reform commission. socialite. In 2001, Amiel made a splash when she osalie Silberman Abella, the first In 2004, she was appointed to the Su- Born in England, Amiel moved with her reported in the British weekly magazine, R Jewish woman appointed to the Su- preme Court, where she has written de- family to Hamilton, Ont., as an adolescent, The Spectator, that the then-French am- preme Court of Canada has been shat- cisions on family law, employment law, but spent years living on her own and bassador to Britain had called Israel “that tering the glass ceiling her entire life. youth criminal justice and human rights. holding various jobs to support herself af- shitty little country” to Black at a private Born to Holocaust survivor parents in She continues to be involved in issues ter her mother and stepfather pushed her dinner party he was hosting.
    [Show full text]
  • Aging Well Through Innovative Care, Education and Research
    Built on Dreams Aging well through innovative care, education and research BAYCREST AND BAYCREST FOUNDATION Annual Report 2012-2013 Guided by our new five-year Strategic Plan, we at Baycrest Health Sciences continue to build on the dreams of our founders. Then, as now, the belief was that the oldest among us should be treated with the utmost respect and cared for with compassion. Close to 100 years later, an exciting new dimension has been added to that dream – namely, a radical shift in thinking about the aging process that promises to transform and enrich the lives of older adults. 1. Introduce The Baycrest Model, an innovative portfolio of high quality aging and brain health services and care approaches that enrich the cognitive, emotional, spiritual, social, and physical well-being of older adults in community, residential and healthcare settings. 2. Disseminate Baycrest’s expertise to maximize the age-related cognitive and mental health of older adults in our community Strategic Goals and across the globe. 3. Attract and retain the best global human resources, while fostering the highest performance in our people. 4. Develop a new comprehensive business model that will achieve financial strength. Raise $600 million in philanthropic support over 10 years; grow revenue from new business development opportunities; secure additional government funding. ANNUAL REPORT 2012-13 1 Message from the Baycrest Board Chair and the President & CEO Built on Dreams the Baycrest way For many, the aging of the global population every 20 years to 65.7 million in 2030, and presents overwhelming challenges. At Baycrest 115.4 million in 2050.
    [Show full text]
  • DCAT MEMBER COMPANY MEETING LOCATOR V. 6 the BENJAMIN Sri Krishna Pharmaceuticals Ltd
    DCAT MEMBER COMPANY MEETING LOCATOR v. 6 THE BENJAMIN Sri Krishna Pharmaceuticals Ltd. Zydus Pharmaceuticals (USA) Inc. Amino Chemicals Ltd. Apogee Pharma, Inc. INTERCONTINENTAL BARCLAY C2 PHARMA AbbVie* Calyx Chemicals & Pharmaceuticals Ltd. ACIC Pharmaceuticals Inc. ChemCon GmbH Advitech SA Concord Biotech Limited Amneal Pharmaceuticals LLC Dipharma Francis Srl ALP Pharm DSM Sinochem Pharmaceuticals AMRI Emergent BioSolutions Asymchem Inc. F.I.S. - Fabbrica Italiana Sintetici S.p.A. Capsugel, Now a Lonza Company* Indena S.p.A. CBC AMERICAS Corp. Jost Chemical Co. CellMark USA, LLC Jubilant Pharma Charioteer Pharmaceutical Co., Ltd., Zhejiang PharmSource, A GlobalData Company Chemical and Pharmaceutical Solutions PolyPeptide Group Chiral Quest Corp. ROHNER Inc. Croda, Inc. SST Corporation DFE Pharma HOTEL 48LEX DPL-US EQ Esteve AB BioTechnologies, Inc. Evonik Corporation AGC Biologics FAREVA SA AiPing Pharmaceutical, Inc. Flavine North America, Inc. Almac Formosa Laboratories, Inc. Aptuit LLC Grifols International S.A. AZAD Fine Chemicals Ltd. Hainan Poly Pharm. Co., Ltd. Cambridge Isotope Laboratories, Inc. Harris Pharmaceutical Groupe Parima Helm AG Navin Fluorine International Limited Hetero USA, Inc. Qualicaps, Inc. Hikal, Ltd. RC2 Pharma Connect LLC Interchem Corporation Recipharm Inventia Healthcare PVT LTD Recro Gainesville LLC Johnson Matthey Reed-Lane, Inc. Kingchem Life Science LLC Sancilio Pharmaceuticals Company, Inc. Please note: Some DCAT member companies have requested not to be listed in the locator. (*) indicates member companies with Business Meeting Spaces in more than one hotel. INTERCONTINENTAL BARCLAY CONT'D LOTTE NY PALACE Legacy Pharmaceutical Packaging AbbVie* Lonza AG* Acella Pharmaceuticals Neuland Laboratories Ltd. Alcami Corporation Orion Group Alembic Pharmaceuticals Limited Par Pharmaceutical, Inc. Aphena Pharma Solutions PCI Pharma Services Aptar Pharma PHF SA Aristo Pharma Polymed Therapeutics, Inc.
    [Show full text]
  • Karen Shepherd, Commissioner Office of The
    1 Nicholas St., Suite 1510, P.O. Box 821, Stn. B, Ottawa K1P 5P9 Tel: 613-241-5179 Fax: 613-241-4758 Email: [email protected] Internet: http://democracywatch.ca Karen Shepherd, Commissioner Office of the Commissioner of Lobbying of Canada 255 Albert Street 10th Floor Ottawa, Ontario K1A 0H2 Tel: 613-957-2760 Fax: 613-957-3078 Email: [email protected] November 4, 2016 RE: Request for investigation and ruling on Liberal Party of Canada fundraising event held by Apotex chairman in August 2015 Dear Commissioner Shepherd, I am writing on behalf of Democracy Watch to request an investigation and ruling on an August 26, 2015 fundraising event for the Liberal Party of Canada hosted by Apotex Inc. chairman Barry Sherman at his home, and attended by Justin Trudeau and then-candidate, now-Liberal MP Michael Levitt. According to an article in the National Post, tickets for the event cost $1,500. You can see that article at: http://news.nationalpost.com/news/canada/canadian-politics/justin-trudeau-fundraiser- picketed-by-jewish-group-over-liberals-support-for-iran-nuclear-deal. At the time of the event, Apotex was registered to lobby the House of Commons (which means it confirmed that it was lobbying at least some MPs, possibly including Mr. Trudeau) and Mr. Sherman was included as a registered lobbyist in that registration. Currently, Apotex (including Mr. Sherman), along with several consultant lobbyists it has hired since March 1, 2016, are all registered to lobby the Prime Minister’s Office. The consultant lobbyists registered to lobby the Prime Minister’s Office on behalf of Apotex are Aaron Dobbin, John Duffy, Andrew Steele, Brian Teefy and Danya Vered (all five work at StrategyCorp Inc.), as well as Lester Scheininger.
    [Show full text]
  • [ Biopharmaceuticals ] Support Programs Invest in Canada to and Innovation Achieve Global Excellence
    [ BIOPHARMACEUTICALS ] SUPPORT PROGRAMS INVEST IN CANADA TO AND INNOVATION ACHIEVE GLOBAL EXCELLENCE A DYNAMIC RESEARCH AND INNOVATION NETWORK A WELCOMING BUSINESS ENVIRONMENT FINANCIAL STABILITY Canada is ranked as the best country for For six consecutive years, the World Economic Canada’s research excellence is recognized in cardiovascular and metabolic disorders, neuroscience, oncology business in the G-20. Forum has declared Canada’s banking system and infectious diseases and vaccines. Canada is a leader in the development of key technology platforms, Source: Forbes and Bloomberg to be the soundest in the world. including stem cells and regenerative medicine, genomics and antibody technologies. Source: World Economic Forum (WEF) ■ British Columbia’s Centre for Drug Research and Development addresses the challenge of fi nding how A HIGHLY EDUCATED WORKFORCE promising health research conducted at the university level can be translated into commercially viable Canada’s workforce is the most highly UNPARALLELED MARKET ACCESS solutions; educated among members of the OECD, Canada’s NAFTA advantage gives investors with half of its working-age population access to 470 million consumers. Many Canadian ■ Genome Alberta, a public not-for-profi t corporation, initiates, funds and manages genomics research having a tertiary-level education. production hubs are actually closer to U.S. markets and partnerships; Source: Organisation for Economic Co-operation than American production sites—of Canada’s and Development (OECD) ■ Saskatoons Vaccine and
    [Show full text]
  • SANOFI DECISION: THREE YEARS LATER* Patrick S
    THE SUPREME COURT’S SANOFI DECISION: THREE YEARS LATER* Patrick S. Smith and Donald M. Cameron** ABSTRACT In 2008, the Supreme Court of Canada’s decision in Apotex Inc. v. Sanofi-Synthelabo Canada Inc. restated the test for anticipation under Canadian patent law to expressly include enablement. Sanofi also provided an analytical approach for obviousness and provided the option of using the “obvious to try” test in areas where inventions are often won by experimentation. This article reviews the most important cases from 2008 to 2011 that have applied the Sanofi decision. The Supreme Court’s Sanofi Decision: Three Years Later* Patrick S. Smith and Donald M. Cameron** . 281 RÉSUMÉ 1.0 Introduction . 282 En 2008, la décision de la Cour suprême du Canada dans l’affaire Apotex Inc. c. 1.1 The New Anticipation Test . 282 Sanofi-Synthelabo Canada Inc. a reformulé le critère de l’antériorité en vertu de la loi 1.2 The New Obviousness Test . 283 canadienne sur les brevets de façon à y inclure la notion de « caractère réalisable ». 1.3 How We Conducted the Review . 283 Elle a aussi établi la méthode analytique à adopter concernant l’évidence, et a offert la 2.0 Anticipation . 284 possibilité d’appliquer le critère de l’« essai allant de soi » dans les domaines où les 2.1 What Did Sanofi Do Regarding Enablement? . 284 inventions sont souvent le fruit de l’expérimentation. L’article passe en revue les plus 2.2 Post-Sanofi Enablement Decisions . 285 importantes causes qui ont utilisé la décision Sanofi entre 2008 et 2011.
    [Show full text]
  • The Evolution of Canadian and Global
    Carleton University The Review of Bill C-91: Pharmaceutical Policy Development under a Majority Liberal Government A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirement for the degree of Master of Arts Institute of Political Economy by Jason Wenczler, M.Sc. Ottawa, Canada September 2009 ©2009, Jason Wenczler Library and Archives Bibliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington Ottawa ON K1A 0N4 Ottawa ON K1A 0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-60270-6 Our file Notre r6f§rence ISBN: 978-0-494-60270-6 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Bibliotheque et Archives Archives Canada to reproduce, Canada de reproduce, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par I'lnternet, preter, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciales ou autres, sur worldwide, for commercial or non­ support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in this et des droits moraux qui protege cette these. Ni thesis. Neither the thesis nor la these ni des extraits substantiels de celle-ci substantial extracts from it may be ne doivent etre imprimes ou autrement printed or otherwise reproduced reproduits sans son autorisation.
    [Show full text]
  • Biomedical Conflicts of Interest: a Defence of the Sequestration Thesis
    Biomedical Conflicts of Interest: a defence of the sequestration thesis Learning from the cases of Nancy Olivieri and David Healy Arthur Schafer, Centre for Professional and Applied Ethics, University of Manitoba, Canada Abstract No discussion of academic freedom, research integrity and patient safety could begin with a more disquieting pair of case studies than those of Nancy Olivieri and David Healy. The cumulative impact of the Olivieri and Healy affairs has caused serious self-examination within the biomedical research community. The first part of the essay analyses this pair of recent academic scandals. The two case studies are then placed in their historical context – that context being the transformation of the norms of science through increasingly close ties between research universities and the corporate world. After a literature survey of the ways in which corporate sponsorship has biased the results of clinical drug trials, two different strategies to mitigate this problem are identified and assessed: a regulatory approach, which focuses on managing risks associated with industry funding of university research, and a more radical approach, the sequestration thesis, which counsels the outright elimination of corporate sponsorship. The reformist approach is criticized and the radical approach defended. Two case studies: Olivieri and Healy The leading individual roles in this diptych are taken by two internationally eminent medical researchers, haematologist Nancy Olivieri and psychiatrist David Healy. The institutional players include one research-intensive university (the University of Toronto) and two affiliated research-intensive teaching hospitals (the Hospital for Sick Children, referred to as “Sick Kids” and the Centre for Addiction and Mental Health, referred to as “CAMH”).
    [Show full text]
  • Dances with the Pharmaceutical Industry
    Commentaire Dances with the pharmaceutical industry Elaine Gibson, Françoise Baylis, Steven Lewis n a recent commentary published in this journal, we, tent with ethical guidelines governing research in Canada,7 along with others, described the relationship of univer- the REB instructed her to disclose her concern to all re- sity-based medical researchers with industry as a risky search participants. When she moved to comply with the I 1 dance with a porcupine. Our focus was the pharmaceutical REB’s directive, Apotex terminated the 2 trials in progress industry and how its fundamental need to satisfy sharehold- in Toronto and Olivieri’s consulting contract for a third in- ers could, and at times did, conflict with a researcher’s ternational trial. As well, Apotex threatened legal action agenda to seek and unveil truth. against Olivieri should she attempt to inform patients or Now, for a close-up view of dance partners wildly out of anyone else of her concerns. Sometime after the trials were step, we turn to the case of Nancy Olivieri. Her stormy rela- terminated, Olivieri identified a second unexpected risk, tionship with Apotex Inc., Toronto’s Hospital for Sick Chil- i.e., that the drug may cause progression of liver fibrosis. dren (HSC) and the University of Toronto has been exten- Patients receiving the drug and the regulatory authorities sively reviewed, not once but twice, in reports that reach were notified directly of this additional risk by Olivieri. diametrically opposite conclusions on some of the major is- During this period, Apotex and the University of Toronto sues at stake.
    [Show full text]
  • Manufacturers That Made Paab Submissions in 2019
    MANUFACTURERS THAT MADE PAAB SUBMISSIONS IN 2019 AbbVie Corporation Medunik Canada Aequus Pharmaceuticals, Inc. Merck Frosst Canada Ltd. Akcea Therapeutics Canada Merus Labs Alk-Abello Pharmaceuticals Inc Mitsubishi Tanabe Pharma America, Inc. Allergan Canada Mylan Pharmaceuticals ULC Amgen Canada Inc. Novadaq Technologies ULC Amicus Therapeutics UK Ltd Novartis Canada Inc. ApoPharma Inc Novartis Consumer Health Apotex Inc. Novo Nordisk Canada Inc. Astellas Pharma Canada, Inc. Otsuka Canada Pharmaceutical AstraZeneca Canada Inc. Paladin Laboratories AVIR Pharma Inc. Pediapharm Bausch & Lomb Canada Inc. PendoPharm Bayer Inc. Pfizer Canada Inc. BioSyent Pharma Inc. Pharm Canada Inc. Boehringer Ingelheim Ltd. Pierre Fabre Dermo-Cosmétique Canada Inc. Boiron Canada Inc. Purdue Pharma Bristol Myers Squibb Reckitt Benckiser Canada Inc. Celgene Recordati Rare Diseases Inc. CSL Behring Canada Inc. Sandoz Canda Inc. Dr. Reddy's Lab. Can. Inc. Sanofi Consumer Health Inc. Duchesnay Inc. Sanofi Pasteur Limited Eli Lilly Canada Inc. Sanofi-Aventis Canada Inc. EMD Serono Searchlight Pharma Inc. Emergent BioSolutions Canada Inc. Seattle Genetics, Inc. Evolus, Inc. Servier Canada Ferring Inc. Shire Canada Inc. Galderma Canada Sprout Pharmaceuticals Canada, Ltd. Genzyme Canada Inc. Stallergenes Canada Inc. Gilead Sciences Canada STI Technologies Limited GlaxoSmithKline Sunovion Pharmaceuticals Inc. Hill Dermaceuticals, Inc. Taiho Pharma Canada Inc. Hoffmann-La Roche Ltd Takeda Canada Indivior Canada Ltd Teligent Canada Inc. Intercept Pharmaceuticals, Inc TerSera Canada Inc. Ipsen Limited Teva Canada Innovation Iroko International LP Teva Canada Limited JAMP Pharma Corporation Tribute Pharmaceuticals Janssen Inc. Valeant Canada Consumer Prods. Kaleo, Inc. Valeant Pharma Knight Therapeutics Inc. Valeo Pharma Inc. Leo Pharma Inc. Valneva Canada Inc. Lundbeck Canada Vertex Pharmaceuticals Inc.
    [Show full text]
  • No 1 CPMK1: 10 5 5 35 Bernard Charles "Barry" Sherman, CM (25
    FINAL EXAM Score: LEGAL SCIENCE STUDY PROGRAM Even Semester 2019 /2020 Subject : Comparative Inheritance Law Day/Date : Wednesday, 17 June 2020 Time : 90 minutes (10.10 to 11.40 WIB) Lecturer : Dr. Wahyuni Retno Wulandari, SH, MH TRISAKTI UNIVERSITY Yulia Fitriliani, SH, MH Exam Type : OPEN BOOK and GADGET Instructions for Questions: a. Do it by typing in Arial font size 12 on A4 size white HVS paper, with 1.5 spacing in PDF format, with the file name: UAS_MATA KULIAH_NAMA MAHASISWA_GENAP 2019-2020 and UPLOAD on Google Classroom, no later than Wednesday, 17 June 2020, no later than 11.40 WIB; b. ADD YOUR NAME, NIM, SUBJECT, and SIGNATURE; c. Students save the answer sheet and file it in one file along with their assignments; d. If cooperation or copy paste is detected, the score obtained is E.; e. Assessment conditions based on rubric. Subject Learning Outcomes (CPMK): CPMK1= Students are able to identify the essence of comparison, comparative legal methods, comparative legal systems (Common law, civil law, Custom, Religion, and socialism) from various countries in the world, in their application to inheritance law (CPP2) CPMK3= Students work independently and / or in groups to criticize complicated cases of inheritance law in various countries with different legal systems and the same legal system, to analyze their differences and similarities (CPKU2) No Weighted Question Quest Score /CPL ion1 CPMK1: Bernard Charles "Barry" Sherman, CM (25 February 1942 - 13 December 2017) is a Canadian entrepreneur and philanthropist who is the chairman and CEO of Apotex Inc. With an estimated net worth of US $ 3.2 billion at the time of his death, according to Forbes, Sherman was the 12th richest Canadian.
    [Show full text]